Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prognostic biomarkers of antipsychotic-induced weight gain

ABSTRACT: Prognostic biomarkers of antipsychotic-induced weight gain

PROVIDER: PRJNA661304 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12582726_1.fastq.gz	Fastqsanger.gz
	SRR12582726_2.fastq.gz	Fastqsanger.gz
	SRR12582727_1.fastq.gz	Fastqsanger.gz
	SRR12582727_2.fastq.gz	Fastqsanger.gz
	SRR12582728_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Prognostic biomarkers of antipsychotic-induced weight gain

Project description:Antipsychotic drugs (APs) are used to treat psychiatric disorders but also have the prominent side effect of weight gain resulting in a higher incidence of metabolic disease in this patient group. While the majority of patients gain significant weight in response to APs some patients are relatively resistant to these effects. APs such as clozapine and olanzapine are deemed to be highly efficacious at treating psychiatric conditions yet they have some of the highest weight gain liabilities. Therefore, there is a need to determine which patients are less susceptible to the metabolic side effects of APs and would be good candidates for drugs such as olanzapine, and conversely, identifying patients that should be prescribed alternative APs with less weight gain liabilities.

2021-01-01 | GSE157438 | GEO

Antipsychotic Weight Gain

Project description:Altered Gene Expression in Antipsychotic Induced Weight Gain

| PRJEB31532 | ENA

The Atypical Antipsychotic Risperidone Targets Central Melanocortin 4 Receptors to Cause Weight

Project description:The Atypical Antipsychotic Risperidone Targets Central Melanocortin 4 Receptors to Cause Weight

| PRJNA666420 | ENA

The Discovery and Validation of AML Prognostic Biomarkers

Project description:The Discovery and Validation of AML Prognostic Biomarkers

| PRJNA805342 | ENA

The Discovery and Validation of AML Prognostic Biomarkers

Project description:The Discovery and Validation of AML Prognostic Biomarkers

| PRJNA805341 | ENA

Array CGH analysis of 56 primary gastric cancers for elucidating prognostic biomarkers

Project description:Array CGH analysis was done with 56 primary gastric cancers to elucidate prognostic biomarkers on the BAC basis. Using the extracted genomic DNA from 56 primary gastric cancers, array CGH was done to elucidate the prognostic biomarkers.

2010-08-10 | E-GEOD-15436 | biostudies-arrayexpress

Integrative Personal Omics Profiles During Periods of Weight Gain and Loss

Project description:A longitudinal study of PBMCs from patients during periods of weight gain and loss in humans was performed.

2018-01-11 | PXD007859 | Pride

Altered adipose lipid mobilization predicts long-term weight gain and impaired glucose metabolism

Project description:Factors predicting body weight gain and associated disturbed glucose metabolism remain to be established. Here we assessed the role of subcutaneous adipocyte lipid mobilization (lipolysis) in spontaneous long-term (>10 years) body weight changes. In two independent clinical cohorts we found that low stimulated lipolysis at baseline correlated inversely with body mass index changes over time. Disturbed lipolysis gave odds ratios of ≥4.6 for weight gain and ≥3.2 for development of insulin resistance and impaired fasting glucose/type 2 diabetes. Baseline adipose mRNA expression of a set of established lipolysis-regulating genes was lower in weight gainers.

2018-04-13 | GSE113080 | GEO

The host & gut microbiome orchestrate smoking cessation-induced weight gain

Project description:The host & gut microbiome orchestrate smoking cessation-induced weight gain

| PRJEB47053 | ENA

A BAFF/APRIL axis regulates obesogenic-diet driven weight gain

Project description:A BAFF/APRIL axis regulates obesogenic-diet driven weight gain

| PRJNA543147 | ENA